Aktienanalyse zu Annovis Bio Inc (ANVS)ANVSAnnovis Bio Inc

Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Annovis Bio Inc is a good buy right now due to its current price of $1.08, which is significantly below its 52-week high of $5.50, indicating a potential for recovery. The RSI is at 58.455, suggesting that the stock is not overbought, while recent insider buying has increased by 673.49%, reflecting confidence in the company's future. However, a major risk is the negative earnings per share (EPS) estimate of -0.30 for the upcoming earnings report on November 11, 2026, which could impact investor sentiment.